文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

T细胞充足脐带血移植在高危及复发难治性儿童髓系恶性肿瘤中取得更优结局

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy.
PubMed 文献 · Blood Adv · 2023-01-01

该研究连续收集2014年1月至2021年12月英国和爱尔兰367例接受T细胞充足脐带血移植(TRCB,112例)或其他细胞来源移植(255例)的儿童AML/MDS患者数据。TRCB队列中51.4%患者移植时MRD阳性、46.4%为难治性疾病、21.4%为二次移植,均高于对照组。多因素分析显示TRCB队列无事件生存率、至复发时间显著改善,慢性GVHD减少,总体生存有改善趋势。

要点

  • TRCB队列中51.4%患者移植时MRD阳性,46.4%为难治性疾病,21.4%有既往移植史,均高于对照组。
  • TRCB队列无事件生存率为64.1%,其中MRD阳性患者50%、MRD阴性患者79%。
  • 多因素分析示TRCB显著改善无事件生存和至复发时间,减少慢性GVHD,总体生存有改善证据。

核心结论

  • 在调整基线特征不平衡后,TRCB队列的无事件生存率、至复发时间显著改善,慢性GVHD减少,总体生存有改善证据。
  • 无论MRD状态如何,TRCB的效应似乎相似。
  • 无血清治疗的脐带血移植可能是儿童髓系恶性肿瘤的最佳移植选择。

研究设计与样本

  • 连续收集英国和爱尔兰2014年1月至2021年12月期间367例接受TRCB(112例)或其他细胞来源(255例)干细胞移植的儿童AML/MDS患者数据。
  • 收集人口学、疾病及治疗资料,包括既往移植、移植时MRD状态、HLA配型、复发、死亡、GVHD和移植相关死亡率。
  • 进行单因素和多因素分析。

主要发现

  • TRCB队列中51.4%患者移植时MRD阳性、46.4%为难治性疾病、21.4%为既往移植后复发,对照组分别为26.1%、8.6%和5.1%。
  • TRCB队列无事件生存率为64.1%,其中MRD阳性患者为50%、MRD阴性患者为79%。
  • 多因素分析显示TRCB队列无事件生存率显著改善、至复发时间显著改善、慢性GVHD显著减少,并有总体生存改善的证据。
  • TRCB的效应似乎不受MRD状态影响。

临床怎么用

  • 作者认为,无血清治疗的脐带血移植可能是儿童髓系恶性肿瘤的最佳移植选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stem cell transplant (SCT) outcomes in high-risk and relapsed/refractory (R/R) pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been historically poor. Cord blood (CB) allows T-cell replete CB transplant (TRCB), enabling enhanced graft-versus-leukemia. We consecutively collected data from 367 patients undergoing TRCB (112 patients) or other cell source (255 patients) SCT for pediatric AML/MDS in the United Kingdom and Ireland between January 2014 and December 2021. Data were collected about the patient's demographics, disease, and its treatment; including previous transplant, measurable residual disease (MRD) status at transplant, human leukocyte antigen-match, relapse, death, graft versus host disease (GvHD), and transplant-related mortality (TRM). Univariable and multivariable analyses were undertaken. There was a higher incidence of poor prognosis features in the TRCB cohort: 51.4% patients were MRD positive at transplant, 46.4% had refractory disease, and 21.4% had relapsed after a previous SCT, compared with 26.1%, 8.6%, and 5.1%, respectively, in the comparator group. Event free survival was 64.1% within the TRCB cohort, 50% in MRD-positive patients, and 79% in MRD-negative patients. To allow for the imbalance in baseline characteristics, a multivariable analysis was performed where the TRCB cohort had significantly improved event free survival, time to relapse, and reduced chronic GvHD, with some evidence of improved overall survival. The effect appeared similar regardless of the MRD status. CB transplant without serotherapy may be the optimal transplant option for children with myeloid malignancy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Horgan C, Mullanfiroze K, Rauthan A, et al. T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy. Blood Adv. 2023. PMID: 36649566. doi:10.1182/bloodadvances.2022009253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。